Search

Your search keyword '"Ostermann, Helmut"' showing total 451 results
Start Over Author "Ostermann, Helmut"
451 results on '"Ostermann, Helmut"'

2. PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial

Author

Kreissl, Stefanie, Goergen, Helen, Buehnen, Ina, Kobe, Carsten, Moccia, Alden, Greil, Richard, Eichenauer, Dennis A, Zijlstra, Josée M, Markova, Jana, Meissner, Julia, Feuring-Buske, Michaela, Soekler, Martin, Beck, Hans-Joachim, Willenbacher, Wolfgang, Ludwig, Wolf-Dieter, Pabst, Thomas, Topp, Max S, Hitz, Felicitas, Bentz, Martin, Keller, Ulrich Bernd, Kühnhardt, Dagmar, Ostermann, Helmut, Hertenstein, Bernd, Aulitzky, Walter, Maschmeyer, Georg, Vieler, Tom, Eich, Hans, Baues, Christian, Stein, Harald, Fuchs, Michael, Diehl, Volker, Dietlein, Markus, Engert, Andreas, and Borchmann, Peter

Published
2021
Full Text
View/download PDF

3. PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial

Author

Borchmann, Peter, Plütschow, Annette, Kobe, Carsten, Greil, Richard, Meissner, Julia, Topp, Max S, Ostermann, Helmut, Dierlamm, Judith, Mohm, Johannes, Thiemer, Julia, Sökler, Martin, Kerkhoff, Andrea, Ahlborn, Miriam, Halbsguth, Teresa V, Martin, Sonja, Keller, Ulrich, Balabanov, Stefan, Pabst, Thomas, Vogelhuber, Martin, Hüttmann, Andreas, Wilhelm, Martin, Zijlstra, Josée M, Moccia, Alden, Kuhnert, Georg, Bröckelmann, Paul J, von Tresckow, Bastian, Fuchs, Michael, Klimm, Beate, Rosenwald, Andreas, Eich, Hans, Baues, Christian, Marnitz, Simone, Hallek, Michael, Diehl, Volker, Dietlein, Markus, and Engert, Andreas

Published
2021
Full Text
View/download PDF

5. Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study

Author

Bekadja, Mohamed, Hamladji, Rose-Marie, Ali, Hocine Ait, Hamdi, Selma, Touhami, Hadj, Mansour, Nourredine Sidi, Willenbacher, Wolfgang, Linkesch, Werner, Nemet, Damir, Pedersen, Robert Shou, Abildgaard, Niels, Laane, Edward, Hein, Marju, Mohty, Mohamad, Eveillard, Jean Richard, Yamani, Abderrazak el, Moreau, Philippe, Sanhes, Laurence, Lepeu, Gérard, Laribi, Kamel, Jourdan, Eric, Fitoussi, Olivier, Allangba, Olivier, Fleury, Joël, Escoffre, Martine, Benramdane, Riad, Cartron, Guillaume, Dine, Gérard, Legouffe, Eric, Harich, Hanns-Detlev, Illmer, Thomas, Dörfel, Steffen, Hannig, Carla Verena, Koenigsmann, Michael, Prange-Krex, Gabriele, Salwender, Hans, Tamm, Ingo, Zeller, Wolfgang, Maasberg, Michael, Schlag, Rudolf, Klausmann, Martine, Uhlig, Jens, Alkemper, Burkhard, Schütz, Stefan, Tessen, Hans-Werner, Mohr, Benno, Schmidt, Peter, Heinrich, Bernhard, Hebart, Holger, Seipelt, Gernot, Zoeller, Thomas, Heits, Frank, Müller-Naendrup, Clemens, Hansen, Richard, Repp, Roland, Von Weikersthal, Ludwig Fischer, Schmits, Rudolf, Heßling, Jörg, Krammer-Steiner, B., Janzen, Viktor, Schauer, Michael, Grüner, Marcus W., Kisro, Jens, Denzlinger, Claudio, Freier, Werner, Junghanss, Christian, Görner, Martin, Laichinger, Katharina, Ostermann, Helmut, Dürk, Heinz, Hess, Georg, Reich, Gernot, Terpos, Evangelos, Dimopoulos, Meletios, Matsouka, Panagiota, Pouli, Anastasia, Anagnostopoulos, Achilles, Masszi, Tamas, Borbényi, Zita, Ivanyi, Janos, Szomor, Arpad, Abadi, Uri, Nagler, Arnon, Magen, Hila, Avivi, Irit, Quitt, Miriam, Palumbo, Antonio, Boccadoro, Mario, De Stefano, Valerio, Za, Tommaso, Vallisa, Daniele, Foa, Roberto, Corso, Alessandro, Bosi, Alberto, Vacca, Angelo, Lanza, Francesco, Palazzo, Giulia, Avvisati, Giuseppe, Cavo, Michele, Ferrara, Felicetto, Consoli, Ugo, Cantonetti, Maria, Angelucci, Emanuele, Califano, Catello, Di Raimondo, Francesco, Guarini, Attilio, Musso, Maurizio, Pizzuti, Michele, Giuliani, Nicola, Ardizzoia, Antonio, Di Renzo, Nicola, Gaidano, Gianluca, Gozzetti, Alessandro, Pitini, Vincenzo, Farina, Gabriella, Centurioni, Riccardo, De Fabritiis, Paolo, Iuliano, Francesco, La Nasa, Giorgio, La Verde, Giacinto, Pane, Fabrizio, Recine, Umberto, La Targia, Maria, Mineo, Giuseppe, Cangialosi, Clotilde, Fagnani, Daniele, Federici, Augusto, Romano, Atelda, Specchia, Giorgina, Storti, Sergio, Bongarzoni, Velia, Bacigalupo, Andrea, Gobbi, Marco, Latte, Giancarlo, Mannina, Donato, Capalbo, Silvana, Lejniece, Sandra, Pečeliūnas, Valdas, Jurgutis, Mindaugas, Stankovic, Svetlana, Legiec, Wojciech, Woszczyk, Dariusz, Hołojda, Jadwiga, Gornik, Slawomir, Pluta, Andrzej, Morawiec-Szymonik, Elzbieta, Kyrcz-Krzemien, Slawomira, Homenda, Wojciech, Grosicki, Sebastian, Sulek, Kazimierz, Lange, Andrzej, Kloczko, Janusz, Starzak-Gwozdz, Jolanta, Hellmann, Andrzej, Komarnicki, Mieczyslaw, Kuliczkowski, Kazimierz, Viveiros, Carolina, Gonçalves, Cristina, Esefyeva, Natalia, Kochkareva, Julia, Kaplanov, Kamil, Volodicheva, Elena, Laricheva, Elena, Dergacheva, Valentina, Chukavina, Marina, Volchenko, Natalia, Nazarova, Irina, Anchukova, Ludmila, Ovanesova, Elena, Gritsenko, Taras, Salogub, Galina, Magomedova, Ludmila, Kuznetsova, Irina, Osyunikhina, Svetlana, Serdyuk, Olga, Karyagina, Elena, Ivanova, Valentina, Černelč, Slovenia Peter, Louw, Vernon, Coetzee, Corlia, Gunther, Karen, Moodley, Dhayanithi, Duran, Soledad, Gutiérrez, Asunción Echeveste, De Oteyza, Jaime Perez, Capote, Francisco Javier, Casanova, Maria, Sanchez, Jesus Martin, Rios-Herranz, Eduardo, Ibañez-Garcia, Jeronima, Herranz, Maria Jose, Hernandez, Belen, Sanchez, Sara Sanchez, Escalante, Fernando, Carnicero, Fernando, Lleonart, Joan Bargay, Gironella, Mercedes, Martínez, Rafael, De La Guia, Ana Lopez, Palomera, Luis, Iglesias, Rebeca, Ramos, Fernando Solano, De La Serna, Javier, Sanchez, Pedro Garcia, Vidal, Juan Besalduch, Mateos, Maria-Victoria, Morfa, Miguel Diaz, Beksac, Turkey – Meral, Vural, Filiz, Aydin, Yildiz, Unal, Ali, Goker, Hakan, Bilgir, Oktay, Guvenc, Birol, Turgut, Mehmet, Ozet, Gulsum Gulistan, Ali, Ridvan, Masliak, Zvenyslava, Kyselyova, Maryna, Glushko, Nataliia, Vybyrana, Renata, Skrypnyk, Igor, Tretyak, Natalya, Kharchevska, Tetiana, Dyagil, Iryna, Popovs'ka, Tetiana, Shimanskiy, Vadim, Lysa, Tamila, Oliynyk, Hanna, Vilchevskaya, Kateryna, Kryachok, Iryna, Popovych, Yuriy, Romanyuk, Natalia, Yushchenko, Natalia, Kaplan, Polina, Rekhtman, Grygoriy, Pylypenko, Halyna, Kozlov, Viktor, Drach, Johannes, Harousseau, Jean-Luc, Einsele, Hermann, Goldschmidt, Hartmut, Facon, Thierry, Michalet, Mauricette, Savchenko, Valery G., De la Rubia, Javier, Cook, Gordon, Mellqvist, Ulf-Henrik, Ludwig, Heinz, Beksac, Meral, Bekadja, Mohamed Amine, Durán, Maria Soledad, Kochkareva, Yulia, Berthou, Christian, Silva, João, Pedersen, Robert Schou, Černelč, Peter, Potamianou, Anna, Couturier, Catherine, Feys, Caroline, and Thoret-Bauchet, Florence

Published
2018
Full Text
View/download PDF

7. PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group

Author

Borchmann, Peter, Goergen, Helen, Kobe, Carsten, Lohri, Andreas, Greil, Richard, Eichenauer, Dennis A, Zijlstra, Josée M, Markova, Jana, Meissner, Julia, Feuring-Buske, Michaela, Hüttmann, Andreas, Dierlamm, Judith, Soekler, Martin, Beck, Hans-Joachim, Willenbacher, Wolfgang, Ludwig, Wolf-Dieter, Pabst, Thomas, Topp, Max S, Hitz, Felicitas, Bentz, Martin, Keller, Ulrich Bernd, Kühnhardt, Dagmar, Ostermann, Helmut, Schmitz, Norbert, Hertenstein, Bernd, Aulitzky, Walter, Maschmeyer, Georg, Vieler, Tom, Eich, Hans, Baues, Christian, Stein, Harald, Fuchs, Michael, Kuhnert, Georg, Diehl, Volker, Dietlein, Markus, and Engert, Andreas

Published
2017
Full Text
View/download PDF

8. Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPPescalated alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group

Author

Borchmann, Peter, Haverkamp, Heinz, Lohri, Andreas, Mey, Ulrich, Kreissl, Stefanie, Greil, Richard, Markova, Jana, Feuring-Buske, Michaela, Meissner, Julia, Dührsen, Ulrich, Ostermann, Helmut, Keller, Ulrich, Maschmeyer, Georg, Kuhnert, Georg, Dietlein, Markus, Kobe, Carsten, Eich, Hans, Baues, Christian, Stein, Harald, Fuchs, Michael, Diehl, Volker, and Engert, Andreas

Published
2017
Full Text
View/download PDF

9. Phase 1b safety and pharmacokinetics of intravenous and oral fosmanogepix in patients with acute myeloid leukaemia and neutropenia.

Author

Cornely, Oliver A, Ostermann, Helmut, Koehler, Philipp, Teschner, Daniel, Limburg, Endrik, Kramer, William G, Barbat, Sara H, Tawadrous, Margaret, and Hodges, Michael R

Subjects
*ACUTE myeloid leukemia, *FUNGAL cell walls, *CD4 lymphocyte count, *INDUCTION chemotherapy, *PATIENT experience, *REMISSION induction
Abstract

Objectives Fosmanogepix (APX001), a first-in-class, intravenous (IV) and oral (PO) antifungal prodrug, is being developed to treat invasive fungal diseases (IFDs). Manogepix (APX001A; active moiety) targets fungal glycosylphosphatidylinositol-anchored cell wall transfer protein 1, inhibiting cell wall synthesis causing loss of viability. This open-label, multicentre, Phase 1b study in patients with AML and neutropenia (absolute neutrophil count <500 cells/μL; >10 days) undergoing chemotherapy aimed to assess tolerability, safety and pharmacokinetics (PK) of IV and PO fosmanogepix. Methods Of 21 adult AML patients undergoing remission induction chemotherapy, 10 received IV fosmanogepix (600 mg; q24h) and 11 received oral fosmanogepix (500 mg; q24h) over 14 days, with a 28 day follow-up. Patients also received remission induction chemotherapy [sequential high-dose cytarabine and mitoxantrone (S-HAM) or 7 + 3 regimen] for AML and IFD prophylaxis (posaconazole). A two-compartmental PK model from previous studies in healthy volunteers was fitted to manogepix plasma data. Results Of 26 fosmanogepix-related adverse events (AEs; IV: 14; PO: 12) in 9 (42.9%) patients [IV: 5 (50%); PO: 4 (36.4%)], none were serious or resulted in fosmanogepix discontinuation. Most frequently occurring fosmanogepix-related AEs were Grade 1/2 nausea [four events in three patients (14.3%)]; vomiting, ALT increase, and delirium [two events; two patients (9.5%) each]. One patient experienced fosmanogepix-related Grade 3 hypertension. Dose-corrected geometric mean ratio of AUC (PO-to-IV) was 95%. Elimination half-lives (∼2 days) were consistent with prior studies in healthy volunteers. Conclusions Fosmanogepix was safe and well tolerated in AML patients with neutropenia receiving remission induction chemotherapy. Safety and PK profiles were comparable to healthy volunteers. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

12. Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO)

Author

Mellinghoff, Sibylle C., Panse, Jens, Alakel, Nael, Behre, Gerhard, Buchheidt, Dieter, Christopeit, Maximilian, Hasenkamp, Justin, Kiehl, Michael, Koldehoff, Michael, Krause, Stefan W., Lehners, Nicola, von Lilienfeld-Toal, Marie, Löhnert, Annika Y., Maschmeyer, Georg, Teschner, Daniel, Ullmann, Andrew J., Penack, Olaf, Ruhnke, Markus, Mayer, Karin, Ostermann, Helmut, Wolf, Hans-H., and Cornely, Oliver A.

Published
2017
Full Text
View/download PDF

13. Expert Report on Immune Thrombocytopenia - Current Diagnostics and Treatment Recommendations from an Expert Group from Austria, Germany, and Switzerland

Author

Matzdorff, Axel, primary, Alesci, Sonja R., additional, Gebhart, Johanna, additional, Holzhauer, Susanne, additional, Hütter-Krönke, Marie Luise, additional, Kühne, Thomas, additional, Meyer, Oliver, additional, Ostermann, Helmut, additional, Pabinger, Ingrid, additional, Rummel, Mathias, additional, Sachs, Ulrich J., additional, Stauch, Thomas, additional, Trautmann-Grill, Karolin, additional, and Wörmann, Bernhard, additional

Published
2023
Full Text
View/download PDF

14. Expertenreport Immunthrombozytopenie - Aktuelle Diagnostik und Therapie

Author

Matzdorff, Axel, primary, Alesci, Sonja R., additional, Gebhart, Johanna, additional, Holzhauer, Susanne, additional, Hütter-Krönke, Marie Luise, additional, Kühne, Thomas, additional, Meyer, Oliver, additional, Ostermann, Helmut, additional, Pabinger, Ingrid, additional, Rummel, Mathias, additional, Sachs, Ulrich J., additional, Stauch, Thomas, additional, Trautmann-Grill, Karolin, additional, and Wörmann, Bernhard, additional

Published
2022
Full Text
View/download PDF

15. JAK inhibition with ruxolitinib in relapsed or refractory classical Hodgkin lymphoma: Final results of a phase II, open label, multicentre clinical trial (JeRiCHO)

Author

Gillessen, Sarah, primary, Pluetschow, Annette, additional, Vucinic, Vladan, additional, Ostermann, Helmut, additional, Kobe, Carsten, additional, Bröckelmann, Paul J., additional, Böll, Boris, additional, Eichenauer, Dennis A., additional, Heger, Jan‐Michel, additional, Borchmann, Sven, additional, Fuchs, Michael, additional, Borchmann, Peter, additional, Engert, Andreas, additional, and von Tresckow, Bastian, additional

Published
2022
Full Text
View/download PDF

19. JAK inhibition with ruxolitinib in relapsed or refractory classical Hodgkin lymphoma: Final results of a phase II, open label, multicentre clinical trial (JeRiCHO)

Author

Gillessen, Sarah, Pluetschow, Annette, Vucinic, Vladan, Ostermann, Helmut, Kobe, Carsten, Broeckelmann, Paul J., Boell, Boris, Eichenauer, Dennis A., Heger, Jan-Michel, Borchmann, Sven, Fuchs, Michael, Borchmann, Peter, Engert, Andreas, von Tresckow, Bastian, Gillessen, Sarah, Pluetschow, Annette, Vucinic, Vladan, Ostermann, Helmut, Kobe, Carsten, Broeckelmann, Paul J., Boell, Boris, Eichenauer, Dennis A., Heger, Jan-Michel, Borchmann, Sven, Fuchs, Michael, Borchmann, Peter, Engert, Andreas, and von Tresckow, Bastian

Abstract

Objectives Patients with classical Hodgkin lymphoma (cHL) relapsing after second-line therapy have a dismal prognosis and novel approaches are required for this patient group. Based on promising (pre-)clinical data and the favourable toxicity profile, we performed a phase II clinical trial with the JAK inhibitor ruxolitinib in patients with relapsed or refractory cHL (r/r cHL). Methods Patients >= 18 years with histologically confirmed r/r cHL who failed second-line treatment were included. Ruxolitinib was given orally at a dose of 25 mg twice daily in continuous 28-day cycles until progression or unacceptable toxicity. Primary endpoint was the PET/CT-based overall response rate (ORR; complete response (CR) or partial response (PR)) after 2 cycles; secondary endpoints included progression-free (PFS) and overall survival (OS) as well as feasibility. The Jericho Trial adopted a 2-stage phase 2 design (Simon 1989). Results Among the 12 included patients in stage 1, 2 had a PR, 3 had a stable disease (SD) and 6 had progressive disease (PD) after two treatment cycles (ORR: 2/12 evaluable patients, 16.7%). Median PFS was 3.6 months, the 1-year OS estimate was 50.6% (median not reached). The toxicity profile was favourable with only one grade IV adverse event (7.1%) reported. Conclusion Ruxolitinib exhibited a favourable side effect profile but modest activity in r/r cHL. Although the formal stopping criterion after stage 1 was not met, the trial did not continue to stage 2 due to the low response and PFS rates observed in stage 1.

Published
2022

23. Primary prophylaxis of invasive fungal infections in patients with haematologic malignancies. 2014 update of the recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology

Author

Tacke, Daniela, Buchheidt, Dieter, Karthaus, Meinolf, Krause, Stefan W., Maschmeyer, Georg, Neumann, Silke, Ostermann, Helmut, Penack, Olaf, Rieger, Christina, Ruhnke, Markus, Sandherr, Michael, Schweer, Katharina E., Ullmann, Andrew J., and Cornely, Oliver A.

Published
2014
Full Text
View/download PDF

25. Treatment of invasive fungal infections in cancer patients—updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)

Author

Mousset, Sabine, Buchheidt, Dieter, Heinz, Werner, Ruhnke, Markus, Cornely, Oliver A., Egerer, Gerlinde, Krüger, William, Link, Hartmut, Neumann, Silke, Ostermann, Helmut, Panse, Jens, Penack, Olaf, Rieger, Christina, Schmidt-Hieber, Martin, Silling, Gerda, Südhoff, Thomas, Ullmann, Andrew J., Wolf, Hans-Heinrich, Maschmeyer, Georg, and Böhme, Angelika

Published
2014
Full Text
View/download PDF

26. Matched-paired analysis of patients treated for invasive mucormycosis: standard treatment versus posaconazole new formulations (MoveOn)

Author

Salmanton-García, Jon, Seidel, Danila, Koehler, Philipp, Mellinghoff, Sibylle, Herbrecht, Raoul, Klimko, Nikolai, Ráčil, Zdeněk, Falces-Romero, Iker, Ingram, Paul, Benítez-Peñuela, Miguel-Ángel, Rodríguez, José Yesid, Desoubeaux, Guillaume, Barać, Aleksandra, García-Vidal, Carolina, Hoenigl, Martin, Mehta, Sanjay, Cheng, Matthew, Klyasova, Galina, Heinz, Werner, Iqbal, Nousheen, Krause, Robert, Ostermann, Helmut, Penack, Olaf, Schalk, Enrico, Sheppard, Donald, Willinger, Birgit, Wisplinghoff, Hilmar, Vehreschild, J Janne, Cornely, Oliver, Vehreschild, Maria, Khedr, Reham Abdelaziz, Arencibia-Núñez, Alberto, Avilés-Robles, Martha, Banke, Ingo, Basher, Ariful, Benachinamardi, Keertilaxmi, Bertz, Harmut, Chakrabarti, Arunaloke, Drgona, Lubos, García-Martínez, Jesús, García-Rodríguez, Julio, Gräber, Sandra, Härter, Georg, Klein, Michael, Kouba, Michal, Lee, Dong-Gun, Le Govic, Yohann, Leo, Fabian, Maertens, Johan, Maschmeyer, Georg, Meintker, Lisa, Mo, Xiao-Dong, Müller, Lena-Katharina, Müller, Nicolas, Nel, Jeremy Stephen, Novák, Jan, Patel, Atul, Pfäfflin, Frieder, Pozo-Laderas, Juan-Carlos, Puerta-Alcalde, Pedro, Rodríguez-Guardado, Azucena, Schroers, Roland, Shekar, Vandana, Shenoi, Susan, Silling, Gerda, Vinh, Donald, Waizel-Haiat, Salomón, Yee Yee, Mandy Yap, Prakash, Peralam Yegneswaran, Žák, Pavel, Groupe d'Étude des Interactions Hôte-Pathogène (GEIHP), Université d'Angers (UA), Service d'Hématologie, CHU Strasbourg, Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Centre d’Etude des Pathologies Respiratoires (CEPR), UMR 1100 (CEPR), Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), Department of Medicine, Medical University Graz, Schwerpunkt Infektiologie, Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg, Department of Haematology and Oncology, Medical Clinic III, University Hospital Munich—Großhadern, Ludwig Maximilian University, Klinik für Hämatologie und Onkologie, Charité, Campus Benjamin Franklin, Department of Haematology/Oncology, Magdeburg University Hospital, McGill University = Université McGill [Montréal, Canada], Medizinische Universität Wien = Medical University of Vienna, University Hospital of Cologne [Cologne], Postgraduate Institute of Medical Education and Research, Laboratoire de psychologie cognitive (LPC), Centre National de la Recherche Scientifique (CNRS)-Aix Marseille Université (AMU), Anofel Cryptosporidium National Network, Department of Hematology, University Hospital Gasthuisberg, Medizinische Klinik, Hämatologie und Onkologie, Klinikum Ernst von Bergmann, Real Expression Artificial Life (IRIT-REVA), Institut de recherche en informatique de Toulouse (IRIT), Université Toulouse 1 Capitole (UT1), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Université Toulouse - Jean Jaurès (UT2J)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Université Toulouse 1 Capitole (UT1), Université Fédérale Toulouse Midi-Pyrénées, Medizinische Klinik A des Universitätsklinikums Münster, Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), University Hospital Gasthuisberg [Leuven], Université Toulouse Capitole (UT Capitole), Université de Toulouse (UT)-Université de Toulouse (UT)-Université Toulouse - Jean Jaurès (UT2J), Université de Toulouse (UT)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université de Toulouse (UT)-Toulouse Mind & Brain Institut (TMBI), Université Toulouse - Jean Jaurès (UT2J), Université de Toulouse (UT)-Université de Toulouse (UT)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université Toulouse Capitole (UT Capitole), Université de Toulouse (UT), Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS), and Université de Tours-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
Male, 0301 basic medicine, Posaconazole, Antifungal Agents, [SDV]Life Sciences [q-bio], Gastroenterology, 0302 clinical medicine, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Amphotericin B, Pharmacology (medical), Prospective Studies, Registries, 030212 general & internal medicine, Child, Prospective cohort study, [SDV.MP.MYC]Life Sciences [q-bio]/Microbiology and Parasitology/Mycology, ComputingMilieux_MISCELLANEOUS, Antiinfective agent, Standard treatment, Middle Aged, 3. Good health, Infectious Diseases, Tolerability, Child, Preschool, Mucorales, Female, medicine.drug, Adult, Microbiology (medical), medicine.medical_specialty, Adolescent, Drug Compounding, Matched-Pair Analysis, 030106 microbiology, Young Adult, 03 medical and health sciences, Pharmacokinetics, Internal medicine, parasitic diseases, medicine, Humans, Mucormycosis, [SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/Parasitology, [INFO]Computer Science [cs], Aged, Pharmacology, business.industry, Infant, Newborn, Infant, Triazoles, medicine.disease, business, MESH: amphotericin b, antifungal agents, cancer, kidney failure, mucormycosis, surgical procedures, operative, suspensions, mortality, posaconazole, Invasive Fungal Infections
Abstract

Background First-line antifungal treatment for invasive mucormycosis (IM) consists of liposomal amphotericin B. Salvage treatment options are limited and often based on posaconazole oral suspension. With the approval of posaconazole new formulations, patients could benefit from improved pharmacokinetics, safety and tolerability. Objectives Our aim was to assess the effectiveness of posaconazole new formulations for IM treatment. Methods We performed a case-matched analysis with proven or probable IM patients from the FungiScope® Registry. First-line posaconazole new formulations (1st-POSnew) and first-line amphotericin B plus posaconazole new formulations (1st-AMB+POSnew) cases were matched with first-line amphotericin B-based (1st-AMB) treatment controls. Salvage posaconazole new formulations (SAL-POSnew) cases were matched with salvage posaconazole oral suspension (SAL-POSsusp) controls. Each case was matched with up to three controls (based on severity, haematological/oncological malignancy, surgery and/or renal dysfunction). Results Five patients receiving 1st-POSnew, 18 receiving 1st-AMB+POSnew and 22 receiving SAL-POSnew were identified. By day 42, a favourable response was reported for 80.0% (n = 4/5) of patients receiving 1st-POSnew, for 27.8% (n = 5/18) receiving 1st-AMB+POSnew and for 50.0% (n = 11/22) receiving SAL-POSnew. Day 42 all-cause mortality of patients receiving posaconazole new formulations was lower compared with controls [20.0% (n = 1/5) in 1st-POSnew versus 53.3% (n = 8/15) in 1st-AMB; 33.3% (n = 6/18) in 1st-AMB+POSnew versus 52.0% (n = 26/50) in 1st-AMB; and 0.0% (n = 0/22) in SAL-POSnew versus 4.4% (n = 2/45) in SAL-POSsusp]. Conclusions Posaconazole new formulations were effective in terms of treatment response and associated mortality of IM. While posaconazole new formulations may be an alternative for treatment of IM, the limited sample size of our study calls for a cautious interpretation of these observations.

Published
2019

30. Leitlinie : Empfehlungen der Fachgesellschaft zur Diagnostik und Therapie h��matologischer und onkologischer Erkrankungen : ICD10: D69.3

Author

Meyer, Oliver, Schweizerische Gesellschaft F��r H��matologie, W��rmann, Bernhard, Pabinger-Fasching, Ingrid, Schweizerische Gesellschaft F��r Medizinische Onkologie, Gesellschaft F��r P��diatrische Onkologie Und H��matologie, Ostermann, Helmut, ��sterreichische Gesellschaft F��r H��matologie & Medizinische Onkologie, Holzhauer, Susanne, Sachs, Ulrich, Deutsche Gesellschaft F��r H��matologie Und Medizinische Onkologie, Matzdorff, Axel, K��hne, Thomas, and Rummel, Mathias

Subjects
Medizin und Gesundheit
Published
2021
Full Text
View/download PDF

36. Stellungnahme zur Nutzenbewertung des G-BA von Arzneimitteln gemäß § 35a SGB V, veröffentlicht am 1. Oktober 2020, Vorgangsnummer 2020-07-01-D-556, IQWiG Bericht Nr. 975

Author

Meyer, Oliver, Ostermann, Helmut, Langer, Florian, Wörmann, Bernhard, Deutsche Gesellschaft Für Transfusionsmedizin Und Immunhämatologie, Gesellschaft Für Thrombose- Und Hämostaseforschung, Deutsche Gesellschaft Für Hämatologie Und Medizinische Onkologie, Deutschland. Gemeinsamer Bundesausschuss, and Matzdorff, Axel

Subjects
Medizin und Gesundheit
Published
2020
Full Text
View/download PDF

37. Leitlinie : Empfehlungen der Fachgesellschaft zur Diagnostik und Therapie hämatologischer und onkologischer Erkrankungen : ICD10: D69.3

Author

Meyer, Oliver, Schweizerische Gesellschaft Für Hämatologie, Wörmann, Bernhard, Pabinger-Fasching, Ingrid, Schweizerische Gesellschaft Für Medizinische Onkologie, Gesellschaft Für Pädiatrische Onkologie Und Hämatologie, Ostermann, Helmut, Österreichische Gesellschaft Für Hämatologie & Medizinische Onkologie, Holzhauer, Susanne, Sachs, Ulrich, Deutsche Gesellschaft Für Hämatologie Und Medizinische Onkologie, Matzdorff, Axel, Kühne, Thomas, and Rummel, Mathias

Subjects
Medizin und Gesundheit
Published
2020
Full Text
View/download PDF

41. Autorenverzeichnis

Author

Dorfmüller, Monika, primary, Dietzfelbinger, Hermann, additional, Abbrederis, Katharina, additional, Agathos, Monika, additional, Bauer, Matthäus, additional, Bumeder, Irmgard, additional, Burghofer, Karin, additional, Fanaei, Sepideh, additional, Fittkau-Tönnesmann, Bernadette, additional, Frick, Eckhard, additional, Frör, Peter, additional, Gallenberger, Sebastian, additional, Giesler, Jürgen M., additional, Graubner, Ulrike B., additional, Greiff, Pfarrer Peter, additional, Grischke, Eva Maria, additional, Hesselbarth, Birte, additional, Heußner, Pia, additional, Hubmann, Max, additional, Kappauf, Herbert W., additional, Lang, Klaus, additional, Mehl, Ullrich, additional, Oduncu, Fuat, additional, Ostermann, Helmut, additional, Petersen, Yvonne, additional, Pouget-Schors, Doris, additional, Riedner, Carola, additional, Roller, Susanne, additional, Scherer, Hans, additional, Schmitt, Doris C., additional, Schmitt, Hermann-Josef, additional, Schreib, Melanie, additional, Staehler, Michael, additional, Stolz, Wilhelm, additional, Weber, Bernhard, additional, Weis, Joachim, additional, Wesselman, Elisabeth, additional, Wilkowski, Ralf, additional, and Winkler, Eva, additional

Published
2013
Full Text
View/download PDF

49. Patterns of Renal Recovery and Toxicity with Novel Agent-Based Induction Triplets in Newly Diagnosed Multiple Myeloma - an Analysis of Two Prospective Studies By the German DSMM Myeloma Study Group

Author

Bachmann, Friederike, primary, Held, Swantje, additional, Engelhardt, Monika, additional, Langer, Christian, additional, Wolleschak, Denise, additional, Fleissner, Janik, additional, Mügge, Lars-Olof, additional, Duerk, Heinz, additional, Schreder, Martin, additional, Schaefer-Eckart, Kerstin, additional, Blau, Igor-Wolfgang, additional, Gramatzki, Martin, additional, Liebisch, Peter, additional, Reichle, Albrecht, additional, Metzler, Ivana, additional, Bassermann, Florian, additional, Metzner, Bernd, additional, Röllig, Christoph, additional, Hertenstein, Bernd, additional, Dechow, Tobias, additional, Jung, Wolfram, additional, Ostermann, Helmut, additional, Hebart, Holger, additional, Maschmeyer, Georg, additional, Salwender, Hans Jürgen, additional, von Lilienfeld-Toal, Marie, additional, Eckardt, Kai-Uwe, additional, Straka, Christian, additional, Einsele, Hermann, additional, and Knop, Stefan, additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results